Switching from onabotulinumtoxina to abobotulinumtoxina in children with cerebral palsy treated for spasticity: A retrospective safety and efficacy evaluation.

CONCLUSION: In children with cerebral palsy, switching from onabotulinumtoxinA to abobotulinumtoxinA is safe and generally well-tolerated and therapeutic efficacy is maintained. PMID: 30931483 [PubMed - as supplied by publisher]
Source: Journal of Rehabilitation Medicine - Category: Rehabilitation Tags: J Rehabil Med Source Type: research